-
Je něco špatně v tomto záznamu ?
Tailoring the physicochemical properties of core-crosslinked polymeric micelles for pharmaceutical applications
Q. Hu, CJ. Rijcken, E. van Gaal, P. Brundel, H. Kostkova, T. Etrych, B. Weber, M. Barz, F. Kiessling, J. Prakash, G. Storm, WE. Hennink, T. Lammers,
Journal of controlled release.
2016 ;
244 (Pt B) :
314-325.
[pub] 20160709
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, práce podpořená grantem
Perzistentní odkaz
https://www.medvik.cz/link/bmc18011121
- MeSH
- akrylamidy chemie MeSH
- doxorubicin chemie MeSH
- micely * MeSH
- molekulová hmotnost MeSH
- nosiče léků chemie MeSH
- polymery chemie MeSH
- reagencia zkříženě vázaná chemie MeSH
- taxoidy chemie MeSH
- uvolňování léčiv MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
To optimally exploit the potential of (tumor-) targeted nanomedicines, platform technologies are needed in which physicochemical and pharmaceutical properties can be tailored according to specific medical needs and applications. We here systematically customized the properties of core-crosslinked polymeric micelles (CCPM). The micelles were based on mPEG-b-pHPMAmLacn(i.e. methoxy poly(ethylene glycol)-b-poly[N-(2-hydroxypropyl) methacrylamide-lactate]), similar to the block copolymer composition employed in CriPec® docetaxel, which is currently in phase I clinical trials. The CCPM platform was tailored with regard to size (30 to 100nm), nanocarrier degradation (1month to 1year) and drug release kinetics (10 to 90% in 1week). This was achieved by modulating the molecular weight of the block copolymer, the type and density of the crosslinking agent, and the hydrolytic sensitivity of the drug linkage, respectively. The high flexibility of CCPM facilitates the development of nanomedicinal products for specific therapeutic applications.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18011121
- 003
- CZ-PrNML
- 005
- 20180404142549.0
- 007
- ta
- 008
- 180404s2016 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jconrel.2016.07.012 $2 doi
- 035 __
- $a (PubMed)27401327
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Hu, Qizhi $u Department of Biomaterials Science and Technology, Section: Targeted Therapeutics, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands; Cristal Therapeutics, Oxfordlaan 55, Maastricht 6229EV, The Netherlands.
- 245 10
- $a Tailoring the physicochemical properties of core-crosslinked polymeric micelles for pharmaceutical applications / $c Q. Hu, CJ. Rijcken, E. van Gaal, P. Brundel, H. Kostkova, T. Etrych, B. Weber, M. Barz, F. Kiessling, J. Prakash, G. Storm, WE. Hennink, T. Lammers,
- 520 9_
- $a To optimally exploit the potential of (tumor-) targeted nanomedicines, platform technologies are needed in which physicochemical and pharmaceutical properties can be tailored according to specific medical needs and applications. We here systematically customized the properties of core-crosslinked polymeric micelles (CCPM). The micelles were based on mPEG-b-pHPMAmLacn(i.e. methoxy poly(ethylene glycol)-b-poly[N-(2-hydroxypropyl) methacrylamide-lactate]), similar to the block copolymer composition employed in CriPec® docetaxel, which is currently in phase I clinical trials. The CCPM platform was tailored with regard to size (30 to 100nm), nanocarrier degradation (1month to 1year) and drug release kinetics (10 to 90% in 1week). This was achieved by modulating the molecular weight of the block copolymer, the type and density of the crosslinking agent, and the hydrolytic sensitivity of the drug linkage, respectively. The high flexibility of CCPM facilitates the development of nanomedicinal products for specific therapeutic applications.
- 650 _2
- $a akrylamidy $x chemie $7 D000178
- 650 _2
- $a reagencia zkříženě vázaná $x chemie $7 D003432
- 650 _2
- $a doxorubicin $x chemie $7 D004317
- 650 _2
- $a nosiče léků $x chemie $7 D004337
- 650 _2
- $a uvolňování léčiv $7 D065546
- 650 12
- $a micely $7 D008823
- 650 _2
- $a molekulová hmotnost $7 D008970
- 650 _2
- $a polymery $x chemie $7 D011108
- 650 _2
- $a taxoidy $x chemie $7 D043823
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Rijcken, Cristianne J F $u Cristal Therapeutics, Oxfordlaan 55, Maastricht 6229EV, The Netherlands.
- 700 1_
- $a van Gaal, Ethlinn $u Cristal Therapeutics, Oxfordlaan 55, Maastricht 6229EV, The Netherlands.
- 700 1_
- $a Brundel, Paul $u Cristal Therapeutics, Oxfordlaan 55, Maastricht 6229EV, The Netherlands.
- 700 1_
- $a Kostkova, Hana $u Institute of Macromolecular Chemistry, the Czech Academy of Sciences, Heyrovský Sq. 2, 162 06 Prague 6, Czech Republic.
- 700 1_
- $a Etrych, Tomas $u Institute of Macromolecular Chemistry, the Czech Academy of Sciences, Heyrovský Sq. 2, 162 06 Prague 6, Czech Republic.
- 700 1_
- $a Weber, Benjamin $u Institute of Organic Chemistry, Johannes Gutenberg-University Mainz, Duesbergweg 10-14, 55128 Mainz, Germany.
- 700 1_
- $a Barz, Matthias $u Institute of Organic Chemistry, Johannes Gutenberg-University Mainz, Duesbergweg 10-14, 55128 Mainz, Germany.
- 700 1_
- $a Kiessling, Fabian $u Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, University Clinic and Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, Aachen 52074, Germany.
- 700 1_
- $a Prakash, Jai $u Department of Biomaterials Science and Technology, Section: Targeted Therapeutics, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands.
- 700 1_
- $a Storm, Gert $u Department of Biomaterials Science and Technology, Section: Targeted Therapeutics, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands; Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht 3584CG, The Netherlands.
- 700 1_
- $a Hennink, Wim E $u Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht 3584CG, The Netherlands.
- 700 1_
- $a Lammers, Twan $u Department of Biomaterials Science and Technology, Section: Targeted Therapeutics, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands; Department of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, University Clinic and Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, Aachen 52074, Germany; Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht 3584CG, The Netherlands. Electronic address: tlammers@ukaachen.de.
- 773 0_
- $w MED00002621 $t Journal of controlled release official journal of the Controlled Release Society $x 1873-4995 $g Roč. 244, č. Pt B (2016), s. 314-325
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27401327 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180404 $b ABA008
- 991 __
- $a 20180404142629 $b ABA008
- 999 __
- $a ok $b bmc $g 1288606 $s 1007933
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 244 $c Pt B $d 314-325 $e 20160709 $i 1873-4995 $m Journal of controlled release $n J Controlled Release $x MED00002621
- LZP __
- $a Pubmed-20180404
